Miguel Islas‐Ohlmayer

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas et al. · Blood · 2018 · 253 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

Paul Shaughnessy, Miguel Islas‐Ohlmayer, Julie A. Murphy et al. · Biology of Blood and Marrow Transplantation · 2010 · 88 citations

Medicine, Hematology, Pharmacoeconomics +17

Experimental Infection of NOD/SCID Mice Reconstituted with Human CD34 ⁺ Cells with Epstein-Barr Virus

Miguel Islas‐Ohlmayer, Angela Padgett‐Thomas, Rana Domiati‐Saad et al. · Journal of Virology · 2004 · 69 citations

Veterinary Medicine, Immunology, Pathology +14

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Ann S. LaCasce, Gregory Bociek, Ahmed Sawas et al. · Blood · 2015 · 61 citations

Medicine, Oncology, Pharmacotherapy +10